Use of Leukocyte-rich and Platelet-rich Fibrin (L-PRF) Adjunct to Surgical Debridement in the Treatment of Stage 2 and 3 Medication-Related Osteonecrosis of the Jaw

Basit Öğe Kaydı
dc.authoridCakir, Merve/0000-0002-4340-0309
dc.authoridYalcin, Gul Merve/0000-0002-7438-5834
dc.authorwosidCakir, Merve/JAA-9861-2023
dc.contributor.authorYalcin-Ulker, Gul Merve
dc.contributor.authorDuygu, Gonca
dc.contributor.authorTanan, Gamze
dc.contributor.authorCakir, Merve
dc.contributor.authorMeral, Deniz Gokce
dc.date.accessioned2024-06-12T10:54:45Z
dc.date.available2024-06-12T10:54:45Z
dc.date.issued2023
dc.departmentTrakya Üniversitesien_US
dc.description.abstractMedication-related osteonecrosis of the jaw (MRONJ) is characterized by exposed necrotic bone persisting for more than 8 weeks in the maxillofacial region in patients using antiresorptive or antiangiogenetic drugs for several treatment options like bone metastasis or osteoporosis. There are several treatment options studied in scientific literature, and one of them with promising results is using platelet concentrates adjunct to surgical therapy. The aim of this study is to examine the therapeutic effect of leukocyte and platelet-rich fibrin (L-PRF) on patients with MRONJ. This 2-centered study investigated patients referred to oral and maxillofacial surgery departments of 2 university clinics between the years 2014 and 2020 with the diagnosis of MRONJ. Demographic data, the indication of the drug usage, drug type, duration, administration route, and systemic comorbidities of the patients were recorded. L-PRF was applied to 20 osteonecrotic lesions of 19 patients following surgical debridement. The male/female ratio was 5/14. Except 1 of the patients, all of the indications of medication were neoplasia-related. The mean follow-up period of patients was 27.9 & PLUSMN;9.2 months. Most common antirezorptive drug was zoledronate (84.2%). Complete resolution was observed in 16 necrosis sites (80%). It could be concluded that the use of L-PRF may represent an important adjunct in the surgical management of MRONJ.en_US
dc.identifier.doi10.1097/SCS.0000000000009161
dc.identifier.endpage1044en_US
dc.identifier.issn1049-2275
dc.identifier.issn1536-3732
dc.identifier.issue3en_US
dc.identifier.pmid36627754en_US
dc.identifier.scopus2-s2.0-85159292957en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage1039en_US
dc.identifier.urihttps://doi.org/10.1097/SCS.0000000000009161
dc.identifier.urihttps://hdl.handle.net/20.500.14551/19169
dc.identifier.volume34en_US
dc.identifier.wosWOS:001012652600091en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherLippincott Williams & Wilkinsen_US
dc.relation.ispartofJournal Of Craniofacial Surgeryen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectBisphosphonateen_US
dc.subjectDenosumaben_US
dc.subjectL-PRFen_US
dc.subjectMRONJen_US
dc.subjectOsteonecrosisen_US
dc.subjectAutologous Platelet Concentratesen_US
dc.subjectSurgical Debridementen_US
dc.subjectBisphosphonate-Related Osteonecrosisen_US
dc.subjectLong-Term Deliveryen_US
dc.subjectAntiresorptive Therapyen_US
dc.subjectGrowth-Factoren_US
dc.subjectCase Seriesen_US
dc.subjectPlasmaen_US
dc.subjectPreventionen_US
dc.subjectManagementen_US
dc.subjectDifferentiationen_US
dc.subjectConcentrateen_US
dc.titleUse of Leukocyte-rich and Platelet-rich Fibrin (L-PRF) Adjunct to Surgical Debridement in the Treatment of Stage 2 and 3 Medication-Related Osteonecrosis of the Jawen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu